Most CAR T cell trials targeting CD19 in hematological malignancies show strong T cell expansion, mainly due to a high load and accessibility of target antigen, the nature of tumor cells (B cells being able to provide co-stimulation), and highly active (second generation) CAR T cells. This evidence concerns the gene CD19 and hematologic disorder.